The humaneered IIIA4 (KB004), is employed in a multi-center Phase 1/2 trial, (http://clinicaltrials.gov/ct2/show/NCT01211691) in patients with EphA3-positive hematologic neoplasms including Chronic Myelogenous Leukemia, Acute Myeloid Leukemia, Acute lymphoblastic leukemia, Myelodysplastic Syndrome who are refractory to, have failed, or have not received standard-of-care treatment (www.kalobios.com). This evidence concerns the gene EPHA3 and chronic myelogenous leukemia, BCR-ABL1 positive.